Sunitinib

نویسندگان

چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Sunitinib Induced Immune Thrombocytopenia

Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ systems including hematologic system. Although the neutropenia and thrombocytopenia commonly happens as Gra...

متن کامل

Sunitinib Induced Immune Thrombocytopenia

Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ systems including hematologic system. Although the neutropenia and thrombocytopenia commonly happens as Gra...

متن کامل

Sorafenib and sunitinib.

Sorafenib (Nexavar ; Bayer Pharmaceuticals, West Haven, CT) (Fig. 1A) and sunitinib (Sutent ; Pfizer Inc., New York, NY) (Fig. 1B) are orally bioavailable, small molecule inhibitors of multiple intracellular and receptor protein kinases that are components of signaling pathways that control tumor growth and angiogenesis. These agents have similar drug profiles and overlapping targets, which are...

متن کامل

sunitinib induced immune thrombocytopenia

sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. it was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. it has several adverse reactions on multi organ systems including hematologic system. although the neutropenia and thrombocytopenia commonly happens as gra...

متن کامل

Acute cardiac failure after sunitinib.

Acute cardiac failure after sunitinib A 54-year-old male with cytokine-refractory metastatic renal cell carcinoma was admitted because of respiratory distress and hypotension. Five years earlier, he has been treated with alpha interferon (IFN) and interleukin-2 (two cycles of 6 weeks, s.c.) for bone, mediastinal lymph node and pulmonary metastases. Six months before admission, sunitinib (50 mg/...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Reactions Weekly

سال: 2021

ISSN: ['1179-2051', '0114-9954']

DOI: https://doi.org/10.1007/s40278-021-95979-y